An increased incidence of lymphomas and skin cancers has been shown in heart transplant recipients compared with the general population. However, the incidence of de novo solid tumors in heart transplant recipients has not been compared with the general population. Accordingly, 851 consecutive adult heart transplant recipients at a single large center were followed up from January 1, 1994, to May 31, 2007, to determine the incidence and type of de novo solid-tumor malignancies. The observed incidence of each cancer type was compared with the expected incidence from the Surveillance Epidemiology End Result database, matching for age, gender, and race. Observed counts divided by expected counts yielded a standardized incidence ratio (SIR), which was tested for significance. Of 851 patients, 73 (8.6%) developed de novo solid-tumor malignancies. Sixty men (83.3%) and 12 women (16.7%) aged 58 +/- 8 years at transplantation were given a diagnosis of cancer at age 62 +/- 8 years. Cancers were divided into 22 categories, and the 3 most frequent cancers were prostate (22), lung (8), and breast (6). SIRs were increased for cervical cancer (SIR 14.3, 95% confidence interval 1.7 to 51.5) and thyroid cancer (SIR 7.7, 95% confidence interval 1.6 to 22.5). Logistic regression showed that age and retransplantation were significant risk factors for cancer. In conclusion, heart transplant recipients did not have a significantly increased frequency of many common malignancies despite long-term immunosuppression.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjcard.2008.10.026DOI Listing

Publication Analysis

Top Keywords

heart transplant
16
transplant recipients
16
general population
12
incidence novo
8
novo solid
8
recipients compared
8
compared general
8
novo solid-tumor
8
solid-tumor malignancies
8
+/- years
8

Similar Publications

Spinal cord injuries (SCIs) can lead to severe neuropathic pain and increased risk of myocardial infarction and heart failure; therefore, the use of analgesics against SCI-induced pain should be minimized because of their adverse effects on the cardiovascular system. Ivabradine, a blocker of hyperpolarization-activated cyclic nucleotide-gated cation (HCN) channels, is used as a bradycardic agent, but recent studies focused on it as an analgesic agent for peripheral neuropathic pain. However, the analgesic effects of ivabradine on central neuropathic pain, such as SCI-induced pain, have not been examined.

View Article and Find Full Text PDF

Introduction: While lymphodepletion is considered a therapeutic effect of rabbit anti-thymocyte globulin (rATG), a concomitant decrease in basophil count (BC) has unknown clinical effect.

Objective: To investigate the association between BC following rATG induction and acute cellular rejection (ACR) during the first post-HTx year.

Methods: Retrospective single-center study included 183 HTx recipients receiving rATG induction between 2010 and 2021 (mean age 52 ± 13 years, 23 % female).

View Article and Find Full Text PDF

Comprehensive Non-invasive Versus Invasive Approach to Evaluate Cardiac Allograft Vasculopathy in Heart Transplantation: The CCTA-HTx Study.

Circ Cardiovasc Imaging

January 2025

Cardiovascular Center Aalst, Onze-Lieve-Vrouwziekenhuis (OLV) Clinic, Aalst, Belgium (M. Belmonte, P.P., M.M.V., M. Beles, H.O., R.S., G.E., M.S., R.D., W.H., J.V.K., J.B., M.V.).

Background: Coronary computed tomography angiography (CCTA) is emerging as a valuable tool for noninvasive surveillance of cardiac allograft vasculopathy (CAV) in patients with heart transplant (HTx). We assessed the diagnostic performance of a comprehensive CCTA-based approach compared with the invasive reference, which includes invasive coronary angiography, intravascular ultrasound, and fractional flow reserve, for detecting CAV.

Methods: This was a multicenter prospective study including 37 patients with HTx who underwent CCTA, invasive coronary angiography, intravascular ultrasound, and fractional flow reserve.

View Article and Find Full Text PDF

E-cigarette or vaping product use-associated lung injury (EVALI) is a potentially severe acute interstitial lung disease primarily observed in the United States, with sporadic cases reported in Europe. EVALI, though rare, could be susceptible to under-diagnosis due to limited awareness and diagnostic suspicion. We present a case of a 19-year-old male in Denmark diagnosed with severe EVALI.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!